Gastro-oesophageal reflux disease and ulcer disease

Alimentary Pharmacology and Therapeutics, Supplement

Volumn 18, Issue 3, 2003, Pages 31-37

  Mahmood, Z ^a   McNamara, D ^a  

^a ADELAIDE AND MEATH HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTACID AGENT; ANTICOAGULANT AGENT; AZAPROPAZONE; CYCLOOXYGENASE 2 INHIBITOR; HISTAMINE H2 RECEPTOR ANTAGONIST; IBUPROFEN; MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; PROTON PUMP INHIBITOR;

CANCER RISK; CONFERENCE PAPER; DIGESTIVE SYSTEM ULCER; ENDOSCOPIC SURGERY; FAT INTAKE; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMAN; LIFESTYLE; PEPTIC ULCER; PRIORITY JOURNAL; RISK FACTOR; SMOKING CESSATION; STOMACH FUNDOPLICATION;

EID: 0242320494     PISSN: 09530673     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0953-0673.2003.01725.x     Document Type: Conference Paper

References (15)

1. Straus WL, Ofman JJ, MacLean C, et al. Do NSADs cause dyspepsia? A Meta-analysis evaluating alternative dyspepsia definitions. Am J Gastro 2002; 97: 1951-8.
2. Hawkey CJ. Non-steroidal anti-inflammatory drugs and peptic ulcers. Br Med J 1990; 300: 278-84.
3. Fries J, Williams CA, Bloch DA, Michel BA. Non-steroidal anti-inflammatory drug-associated gastropathy. Incidence and risk factor model. Am J Med 1991; 91: 213-22.
4. Griffin MR, Piper JM, Daugherty JR, Snowden M, Ray WA. Non-steroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 1991; 114: 257-63.
5. Wolfe MM, Lichtenstein DR, Sing G. Gastrointestinal toxicity of non-steroidal anti-inflammatory. N Eng J Med 1999; 340: 1888-899.
6. Weil J, Colin-Jones D, Langman M, et al. Prophylactic aspirin and risk of peptic ulcer bleeding. Br Med J 1995; 310: 827-30.
7. Slattery J, Warlow CP, Shoeeock CJ, Langman MJS. Risks of gastrointestinal bleeding during secondary prevention of vascular events with aspirin - Analysis of gastrointestinal bleeding during the UK-TIA Trial. GUT 1995; 37: 509-11.
8. Lanas A, Serrano P, Bajador E, Esteva F, Benito R, Sainz R. Evidence of aspirin use in both upper and lower gastrointestinal perforation. Gastroenterol 199; 7: 683-9.
9. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to the use of nonsteroidal anti-inflammatory drugs: a meta-analysis. Ann Intrn Med 1991; 115: 787-96.
10. Langman MJS, Weil J, Wainwright P, et al. Risk of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343: 1075-8.
11. Henry D, Lim LL-Y, Garcia Rodriquez LA, et al. The variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 1996; 312: 1563-6.
12. Garcia Rodriguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-ste-roidal anti-inflammatory drugs. Lancet 1994; 343: 769-72.
13. Shorr RI, Ray WA, Daugherty JR, Griffin MR. Concurrent use of non-steroidal anti-inflammatory and oral anticoagulants places elderly persons at high risk for haemorrhagic peptic ulcer disease. Arch Intern Med 1993; 153: 1665-70.
14. Piper JM, Ray WA, Daugherty JR, Griffin MR. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med 1991; 114: 735-40.
15. Chevat C, Pena BM, Al MJ, Rutten FF. Healthcare resource utilisation and cost of treating NSAID-associated gastrointestinal toxicity. A multinational perspective. Pharmacoeconomics 2001; 19: 17-32.